7p21.1) has been observed in B-NHL (Bea et al., 2005) and, consistent with these results, we found copy number gains of HDAC9, including high-level amplifications, in 46.3% (25/54) of DLBCL patients (Fig. S1). This evidence concerns the gene HDAC9 and diffuse large B-cell lymphoma.